RUNX1 and acute myeloid leukemia: The multitude of molecular markers in AML detectable by standard myeloid NGS panels (e.g., RUNX1, EZH2, or spliceosome mutations), offers the possibility of performing molecular minimal residual disease (MRD) monitoring in virtually every patient.